PT  - JOURNAL ARTICLE
AU  - Anuforo, Anderson
AU  - Aneni, Ehimen
AU  - Akintoye, Emmanuel
AU  - Anikpezie, Nnabuchi
AU  - Patel, Smit D.
AU  - Soipe, Ayorinde
AU  - Olojakpoke, Eloho
AU  - Burke, Devin
AU  - Latorre, Julius Gene
AU  - Khandelwal, Priyank
AU  - Chaturvedi, Seemant
AU  - Ovbiagele, Bruce
AU  - Otite, Fadar Oliver
TI  - Trends in age, sex and racial differences in the incidence of infective endocarditis in Florida and New York
AID  - 10.1101/2023.05.17.23290144
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.05.17.23290144
4099  - http://medrxiv.org/content/early/2023/05/24/2023.05.17.23290144.short
4100  - http://medrxiv.org/content/early/2023/05/24/2023.05.17.23290144.full
AB  - Background How the incidence of infective endocarditis (IE) changed in various age, sex and racial/ethnic subgroups of the United States along with the worsening opioid epidemic over the last decade is unknown.Methods We utilized data from the 2007-2018 State Inpatient Databases (SID)) of two large demographically diverse states (Florida and New York) to conduct a retrospective cohort study. Cases of incident IE identified using validated International Classification of Diseases codes were combined with census data to compute age, sex- and race-specific incidence. Joinpoint regression was used to quantify the annualized percentage change (APC) in incidence over time.Results Of 98,221 incident IE admissions, 70.0% were Non-Hispanic White (NHW) and 60.6% were ≥ 65 years old (yo). The average annual age and sex-standardized incidence of IE in cases/100,000 population was 19.2 (95%CI 18.7-19.6) but this varied by age, sex and race. Incidence was ≈20% higher in men (20.9 [95%CI 20.2-21.7]) compared to women (17.5 [95%CI 16.8-18.2]) and increased with age in both sexes. Incidence was higher in Non-Hispanic Blacks (NHB); 22.5(95%CI 21.0-23.9) compared to NHW: 20.0(95%CI 19.3 to 20.6), Hispanic: 13.2(95%CI 12.3-14.1) and Asian/Pacific Islander patients: 5.9(95%CI 4.7 to 7.1). The age and sex-standardized incidence did not change over time (APC 0.5%, p=0.646). However, incidence increased in women 18-44 (APC 11.0%, p<0.001), men 18-44 (APC 7.3, p<0.001) and 45-64 yo (APC 1.5%, p=0.002) but declined in women ≥ 65 yo (APC −2.8, p=0.049). Most of this increased incidence occurred in NHW women 18-44 (APC 16.6%, p<0.001), NHW men 18-44 (APC 10.6%, p<0.001), NHW men 45-64 (APC 2.8%, p<0.001) and Hispanic Men 18-44 yo (APC 5.6%, p<0.001). Incidence did not change over time in these age/sex groups of NHB and in other age/sex groups. Prevalence of opioid use disorder increased by >2-fold in all age/sex groups over time but the pace of increase was faster in NHW women and men 18-44 yo compared to other races of similar demography (p-for-time interaction <0.001).Conclusion Over the last two decades, among residents of Florida and New York, incidence of IE increased in several demographic groups, but the most prominent rise was among young NHWs, particularly young NHW women.Competing Interest StatementDr Chaturvedi is an associate editor for the Stroke journal and Dr Ovbiagele is Editor-in-Chief of the Journal of the American Heart Association. The other authors have no relevant disclosures.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll datasets used in this study can be obtained from the Healthcare Cost and utilization project